Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1977 Dec;12(6):655–659. doi: 10.1128/aac.12.6.655

Polymyxin B and Rifampin: New Regimen for Multiresistant Serratia marcescens Infections

R C Ostenson 1, B T Fields 1, C M Nolan 2
PMCID: PMC429999  PMID: 201214

Abstract

Polymyxin B and rifampin were given to 12 patients with multi-drug-resistant nosocomial Serratia marcescens infections. Eight cures were achieved; drug hepatotoxicity occurred once; one fatal suprainfection was encountered; and two patients died during therapy of causes related to severe underlying illnesses. Polymyxin B and rifampin were uniformly synergistic in vitro against the infecting strains and against 40 additional clinical isolates of S. marcescens.

Full text

PDF
655

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amirak I. D., Williams R. J., Noone P., Wills M. R. Amikacin resistance developing in patients with Pseudomonas aeruginosa bronchopneumonia. Lancet. 1977 Mar 5;1(8010):537–538. doi: 10.1016/s0140-6736(77)91391-5. [DOI] [PubMed] [Google Scholar]
  2. Craven P. C., Jorgensen J. H., Kaspar R. L., Drutz D. J. Amikacin therapy of patients with multiply antibiotic-resistant Serratia marcescens infections: development of increasing resistance during therapy. Am J Med. 1977 Jun;62(6):902–910. doi: 10.1016/0002-9343(77)90659-3. [DOI] [PubMed] [Google Scholar]
  3. Farmer J. J., 3rd, Davis B. R., Hickman F. W., Presley D. B., Bodey G. P., Negut M., Bobo R. A. Detection of Serratia outbreaks in hospital. Lancet. 1976 Aug 28;2(7983):455–459. doi: 10.1016/s0140-6736(76)92539-3. [DOI] [PubMed] [Google Scholar]
  4. Hoeprich P. D. The polymyxins. Med Clin North Am. 1970 Sep;54(5):1257–1265. [PubMed] [Google Scholar]
  5. Meyer R. D., Lewis R. P., Carmalt E. D., Finegold S. M. Amikacin therapy for serious gram-negative bacillary infections. Ann Intern Med. 1975 Dec;83(6):790–800. doi: 10.7326/0003-4819-83-6-790. [DOI] [PubMed] [Google Scholar]
  6. Meyer R. D., Lewis R. P., Halter J., White M. Gentamicin-resistant Pseudomonas aeruginosa and Serratia marcescens in a general hospital. Lancet. 1976 Mar 13;1(7959):580–583. doi: 10.1016/s0140-6736(76)90370-6. [DOI] [PubMed] [Google Scholar]
  7. Overturf G. D., Zawacki B. E., Wilkins J. Emergence of resistance to amikacin during treatment of burn wounds: the role of antimicrobial susceptibility testing. Surgery. 1976 Feb;79(02):224–228. [PubMed] [Google Scholar]
  8. Tally F. P., Louie T. J., Weinstein W. M., Bartlett J. G., Gorbach S. L. Amikacin therapy for severe gram-negative sepsis. Emphasis on infections with gentamicin-resistant organisms. Ann Intern Med. 1975 Oct;83(4):484–488. doi: 10.7326/0003-4819-83-4-484. [DOI] [PubMed] [Google Scholar]
  9. Thomas F. E., Jr, Leonard J. M., Alford R. H. Sulfamethoxazole-trimethoprim-polymyxin therapy of serious multiply drug-resistant Serratia infections. Antimicrob Agents Chemother. 1976 Feb;9(2):201–207. doi: 10.1128/aac.9.2.201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Tillotson J. R., Finland M. Bacterial colonization and clinical superinfection of the respiratory tract complicating antibiotic treatment of pneumonia. J Infect Dis. 1969 Jun;119(6):597–624. doi: 10.1093/infdis/119.6.597. [DOI] [PubMed] [Google Scholar]
  11. Traub W. H., Kleber I. In vitro additive effect of polymxin B and rifampin against Serratia marcesen. Antimicrob Agents Chemother. 1975 Jun;7(6):874–876. doi: 10.1128/aac.7.6.874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Weinstein R. J., Young L. S., Hewitt W. L. Comparison of methods for assessing in vitro antibiotic synergism against Pseudomonas and Serratia. J Lab Clin Med. 1975 Nov;86(5):853–862. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES